Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Part of paid clinical trials in Maywood, Illinois.

Sponsor
Loyola University
Study ID
NCT05554068
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Shingles

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Shingrix — DRUG
    Shingrix vaccine will be given to all eligible patients at one to three year post allogeneic stem cell transplantation.

Study Details

This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.

Key Dates

Start date
Mar 7, 2023
Status verified
Mar 2023
Primary completion
Mar 7, 2025
Completion
Nov 1, 2026

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Shingrix
    Patients 1-3 years post transplant will receive the Shingrix vaccine in standard dosing and schedule.

Primary Outcome Measure

Cell mediated and humoral immune response [ Time Frame: Measured one month following eh last dose of vaccine received ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Loyola University Medical CenterMaywoodIllinois60153
Patrick Hagen

Find similar trials in Maywood, IL

By research site
Loyola University Medical Center· Maywood, IL